Recent results have demonstrated strong in vivo evidence for protection against development of fatty liver by GPR119 agonist APD668 (4-[[1-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]-1-piperidinecarboxylic acid,1-methylethyl ester) in a mouse model of NASH. The gene discussed is GPR119; the disease is fatty liver disease.